论文部分内容阅读
1932年Northrop等首先从动物胰脏中,获得糜蛋白酶之结晶,具有消化蛋白质的作用。至1950年后,各国医学界始开始研究并应用于临床各科,如:炎症、溃疡、血肿、脓胸等疾病的治疗。而应用于眼科临床,应归功于Barraquer(1958)之研究。氏认为a—糜蛋白酶对睫状刃带有选择性生化作用,可溶解睫状刃带,而有助于内障之囊内摘出,引起了眼科学界广泛的兴趣与注意。嗣后,文献报告日渐增多,今综合手头文献,求教于同道先进。
In 1932, Northrop and other animals first from the pancreas, chymotrypsin obtained crystallization, with the role of digestion of protein. By 1950, the medical community in all countries began to study and apply to clinical departments, such as: inflammation, ulcers, hematoma, empyema and other diseases. The application to ophthalmology is due to Barraquer’s (1958) study. ’S view that a-chymotrypsin has a selective biochemical effect on the ciliary margin, which can dissolve the ciliary marginal zone, which helps to extract the cataract capsule, causing widespread interest and attention of the ophthalmology community. Subsequently, the number of literature reports increased day by day, this comprehensive hand-written literature, advice to fellow advanced.